DxS working on Erbitux companion diagnostic
This article was originally published in The Gray Sheet
Executive Summary
Molecular diagnostics firm DxS will develop a K-RAS gene mutation test for use as a companion diagnostic for the metastatic colorectal cancer drug Erbitux (cetuximab) under a collaboration with the drug's developers, Bristol-Myers Squibb and Eli Lilly/ImClone, announced Sept. 2. If approved by FDA, the DxS TheraScreen test would be used to determine which potential Erbitux patients have K-RAS mutations in codons 12 and 13. The use of monoclonal antibody epidermal growth factor receptor (EGFR) inhibitors like Erbitux is not recommended for the treatment of colorectal cancer with K-RAS mutations in codon 12 or 13, DxS notes. DxS inked a similar deal with Amgen for its colorectal cancer drug Vectibix (panitumumab) last December (1"The Gray Sheet" Dec. 8, 2008)
You may also be interested in...
Companion Diagnostics Spark Pharma Deals, But Still Mostly For Cancer
An inaugural review of the diagnostics sector newly published by PricewaterhouseCoopers contends that growing interest in personalized medicine is a key factor driving partnering deals between pharmaceutical companies and diagnostics developers
DxS Plans PMA For Companion Test To Amgen Colorectal Cancer Drug
Personalized medicine company DxS is preparing a PMA application for a companion diagnostic to Amgen's colorectal cancer drug Vectibix, supported by clinical utility data from a recent Amgen-sponsored clinical trial, according to DxS CEO Stephen Little
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.